M. Agarwal

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes

L. Been, D. Angiolillo, F. Franchi, 2020, JACC. Basic to translational science.

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus

L. Been, V. Kairouz, D. Angiolillo, 2019, JACC. Basic to translational science.

Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study

L. Been, J. Moon, V. Kairouz, 2019, Thrombosis and Haemostasis.

P1930Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study

V. Kairouz, D. Angiolillo, F. Franchi, 2019, European Heart Journal.

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study

L. Been, R. Mehran, U. Baber, 2020, Journal of the American Heart Association.

Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Results of the SWAP (Switching Antiplatelet Therapy)-4 Study

J. Moon, D. Angiolillo, F. Franchi, 2018 .

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the CANTIC Study

L. Been, D. Angiolillo, F. Franchi, 2019, Circulation.